Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Practical considerations for treating elderly and frail patients with multiple myeloma

Hira Mian • 30 Oct 2023
IMS 2023
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide
MAIA

Hira Mian, MD, McMaster University, Hamilton, Canada, discusses the standard of care (SOC) for elderly and frail patients with multiple myeloma, and comments on the importance of optimizing treatment approaches in order to improve patient quality of life (QoL). Dr Mian further elaborates on the role of triplet regimens in this patient population, highlighting the importance of mitigating treatment-related toxicities. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hira Mian

1:45
Outcomes for patients with multiple myeloma who are TCE and BCMA-exposed are poor
Hira Mian • 10 Dec 2023
1:47
Trials exploring the safety and efficacy of modakafusp alfa in R/R multiple myeloma: IINNOVATE
Hira Mian • 30 Oct 2023
1:53
A prognostic survival model incorporating PROs for elderly patients with multiple myeloma
Hira Mian • 30 Oct 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals